&lt;h2&gt;An Overview of Lenacapavir (Sunlenca&amp;reg;)&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is a drug that the FDA has approved for treating HIV. It can be administered through injections or tablets and has a long-acting effect. It belongs to a group of HIV capsid inhibitors that target the structure of the virus. When prescribed, Lenacapavir is typically combined with other antiretroviral drugs that are taken daily as tablets. The specific combination of drugs is carefully selected based on the individual&#39;s HIV resistance to ensure the most effective treatment.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is currently being investigated as an experimental antiretroviral (ARV) drug for pre-exposure prophylaxis (PrEP), which aims to prevent HIV transmission. Ongoing clinical trials are evaluating the effectiveness of Lenacapavir in this regard, assessing its potential as a preventive option.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;New HIV Medication:&amp;nbsp;Lenacapavir (Sunlenca&amp;reg;)&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is a medication used to treat HIV, and it is sold under the brand name Sunlenca. It is specifically designed for people who have developed resistance to other HIV antiretroviral medications.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is a long-acting medication that is given through injections or tablets. It belongs to a class of drugs called HIV capsid inhibitors. Your doctor will prescribe Lenacapavir and other antiretroviral drugs, usually taken as daily tablets. The combination of drugs is carefully chosen based on your HIV resistance to ensure the most effective treatment.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Taking Lenacapavir and other HIV medications as prescribed is crucial. Each drug class works in different ways to fight HIV. The goal of HIV treatment is to lower the level of HIV in your body, known as the viral load, to an undetectable level (usually less than 50 copies of the virus per ml of blood). Adhering to treatment and achieving an undetectable viral load can protect your immune system and prevent you from transmitting HIV to others during sexual activities.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir, also known as GS-6207, is a type of medication that inhibits the capsid of the HIV-1 virus. In lab tests with MT-4 cells, lenacapavir was shown to be anti-HIV, with an EC50 (effective concentration that stops 50% of viral replication) of 100 pM. Also, when tested against 23 different HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs), lenacapavir showed a mean EC50 of 50 pM, ranging from 20 to 160 pM. These findings highlight the potent anti-HIV effects of lenacapavir against various HIV-1 strains in different cell types.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;What is Injectable PrEP?&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Injectable pre-exposure prophylaxis (PrEP) refers to a form of HIV prevention that involves the use of injectable medications to reduce the risk of acquiring HIV. People who are at a high risk of contracting HIV, such as those who have multiple sexual partners or are in serodiscordant relationships (where one partner is HIV-positive and the other is not), typically use PrEP.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;h2&gt;Lenacapavir is on trial for HIV PrEP injection&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is an experimental antiretroviral (ARV) drug currently being investigated as a potential product for pre-exposure prophylaxis (PrEP). It is being studied in clinical trials to assess its effectiveness in preventing HIV transmission.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is the second injectable ARV being tested in late-stage efficacy trials for PrEP, with the first one,&amp;nbsp;&lt;a href=&quot;https://www.pulse-clinic.com/injectable-prep-could-be-approved-in-2022-cabotegravir&quot;&gt;Cabotegravir&lt;/a&gt; for PrEP, receiving approval from the FDA in December 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;Cabotegravir &amp;amp; Lenacapavir for PrEP&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;One significant difference between lenacapavir and injectable Cabotegravir for PrEP (CAB for PrEP) is the method of administration.&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is being studied as a subcutaneous injection, allowing for self-injection. In contrast, CAB for PrEP is administered as an intramuscular injection in the buttocks and requires privacy. Gilead, the pharmaceutical company, is conducting two Phase III trials to evaluate the efficacy of lenacapavir as a six-month injection for PrEP.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Lenacapavir is the second injectable ARV to be tested in late-phase efficacy trials for PrEP. In December 2021, the FDA approved the first,Cabotegravir for PrEP.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;The pharmaceutical company Gilead is currently conducting two Phase III clinical trials to assess the efficacy of lenacapavir as a six-month injection for HIV prevention. These studies aim to determine the safety and effectiveness of lenacapavir as a new pre-exposure prophylaxis (PrEP) option to prevent HIV transmission.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;The clinical trial that aims to assess the effectiveness and safety of subcutaneous (under the skin) injections of long-acting lenacapavir as pre-exposure prophylaxis (PrEP) for HIV prevention. It includes cisgender men, transgender women, transgender men, and gender nonbinary individuals aged 16 years and older who engage in sexual activities with male partners and are at risk of HIV infection.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;The study started on June 28, 2021, and is estimated to have its primary completion in January 2024. The overall completion of the study is projected to be in April 2027. The trial is designed as a double-blind, multicenter, and randomized study, meaning that participants and researchers are unaware of the treatment assignment, and the study takes place across multiple locations. The objective is to gather robust data on the efficacy and safety of lenacapavir as a long-acting HIV prevention option&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Conclusion&lt;/span&gt;&lt;/h2&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;In conclusion, LENACAPAVIR has shown great potential as both an HIV treatment and an injectable option for pre-exposure prophylaxis (PrEP). Its ability to inhibit the HIV-1 virus by targeting the capsid has demonstrated strong anti-HIV activity in laboratory tests using different cell types.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;For &lt;a href=&quot;https://www.pulse-clinic.com/hiv-treatment&quot;&gt;HIV treatment&lt;/a&gt;, LENACAPAVIR has received FDA approval for use in heavily treatment-experienced adults with multidrug-resistant HIV, providing an additional treatment option for individuals who have developed resistance to other antiretroviral drugs.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;As an injectable PrEP, LENACAPAVIR is being investigated as a potential alternative for preventing HIV transmission. Its subcutaneous administration allows for self-injection, distinguishing it from other injectable PrEP options that require intramuscular injections and more privacy. Ongoing Phase III clinical trials are assessing the effectiveness of LENACAPAVIR as a six-month injection for PrEP.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span data-preserver-spaces=&quot;true&quot;&gt;Overall, LENACAPAVIR presents a novel approach to both HIV treatment and prevention. Its potent antiretroviral properties and long-acting injectable formulation make it a promising choice for individuals living with HIV and those at risk of HIV infection. Further research and clinical studies will provide additional information on its effectiveness and safety in diverse populations.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;

Lenacapavir (Sunlenca®) as HIV Treatment & Injectable HIV PrEP

Lead, Venous, with Demographics, Blood

Lead, Nails

Daily HIV PrEP vs PrEP on demand

Lenacapavir (Sunlenca®) as HIV Treatment & Injectable HIV PrEP

WHAT ELSE DO YOU NEED TO KNOW